Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...

Vtama is projected to contribute $150 million in 2025 revenue, supported by its new label approval for atopic dermatitis. Nexplanon is expected to reach at least $1 billion in revenue for 2025. Q4 ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Sequential Skin Ltd, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, are proud to announce that they have been awarded the prestigious UK-Singapore ...